Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis

CONCLUSION: Our retrospective analysis in a large cohort of TNBC patients with residual disease after NACT confirms the benefit of adding a postoperative treatment to reduce risk of relapse and death. Based on these results, we suggest that the adjuvant therapy based on metronomic cyclophosphamide and methotrexate deserves further investigation in this patients population.PMID:34407499 | DOI:10.1016/j.breast.2021.08.004

Source: Breast - August 18, 2021 Category: Cancer & Oncology Authors: Nadia Bianco Antonella Palazzo Eleonora Pagan Vincenzo Bagnardi Monica Milano Ana Paula De Maio Marco Colleoni Source Type: research